Ontology highlight
ABSTRACT: Background
Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD.Methods
Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and
SUBMITTER: Sridhar S
PROVIDER: S-EPMC6339432 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature